Background Non-Hodgkin's lymphoma (NHL) of bone is a rare musculoskeletal malignancy accounting for fewer than 7% of bone cancers. Traditionally, we have treated patients who have NHL of bone with chemotherapy and radiation therapy, but the role of radiotherapy in disease management and patient functional outcomes after treatment have not been well studied. We investigated the survival advantage of radiotherapy in a large cohort of patients with NHL of bone and assessed associated patient complications of radiotherapy.
Questions/purposes The objective of this study was to compare patients treated for NHL of bone with and without radiation in terms of (1) overall survival; (2) pretreatment complications; (3) posttreatment complications; and (4) functional outcomes using the Musculoskeletal Tumor Society (MSTS) score. Methods A retrospective analysis of all patients with biopsy-proven NHL of bone diagnosed at our institution between 1985 and 2013 was undertaken; 70 patients met our criteria for inclusion with minimum followup of 6 months (median, 55 months; range, 10-219 months). Overall survival at 5 and 10 years was estimated and compared between two groups of patients: one group treated with systemic therapy alone (chemotherapy, rituximab; 46 patients [66%]) and the other with combined modality therapy (systemic therapy and radiotherapy; 24 patients [34%]). During the period in question, indications for radiotherapy included bulky disease, an abbreviated course of systemic therapy, and an incomplete response to systemic therapy. Patients not meeting these criteria generally received systemic therapy alone. With the available sample size, it was estimated that a difference in survival of approximately 30% would have to be present for detection with 80% power (a = 0.05, b = 0.2, n = 70, D = 30%). Pretreatment and posttreatment complications occurring in both patient groups were retrospectively reviewed with special emphasis on fracture healing after treatment. MSTS scores were obtained for 45 patients with appendicular tumors at a median followup of 42 months (range, 10-215 months). Results With the data available, no difference in Kaplan-Meier survivorship was observed between patients treated with and without radiation at 5 years (98%; 95% confidence interval [CI], 93%-100% versus 95%; 95% CI, 85%-100%; p = 0.281). Patients who were treated with radiation were Each author certifies that he, or a member of his immediate family, has no funding or commercial associations (eg consultancies, stock ownership, equity interest, patent/licensing, arrangements, etc) that might pose a conflict of interest in connection with the submitted article. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research 1 editors and board members are on file with the publication and can be viewed on request. Clinical Orthopaedics and Related Research 1 neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA approval status, of any drug or device before clinical use. Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained. This work was performed at Rush University Medical Center, Chicago, IL, USA.
Introduction
Non-Hodgkin's lymphoma (NHL) of bone is a rare musculoskeletal malignancy accounting for fewer than 7% of bone cancers [49] . NHL of bone affects patients of all ages but displays a predisposition for older adults (aged C 60 years) [29] . Progressive ''bone pain'' is the most common presenting symptom; however, the disease may be unrecognized until complications such as pathologic fracture arise. Historically, bone lymphomas, originally termed ''reticulum-cell sarcoma,'' were treated with surgical resection and radiotherapy [34, 50] . The sensitivity of bone lymphomas to nonoperative therapies, primarily chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), in recent decades has obviated the need for surgical resection in most cases. The evolution in care has been paralleled by substantial improvements in patient survival. More recently, outcomes have been bolstered by the addition of rituximab to systemic therapy regimens (R-CHOP) with multiple studies reporting improvements in patient overall (OS) and disease-free survival [1, 39, 41] .
NHL of bone remains an uncommon and incompletely understood clinical entity. Because of its relative rarity, many aspects of management remain controversial [16] . At present it is not known if radiotherapy is crucial in management or if patients can be sufficiently treated with systemic therapy alone [42] . Radiation has known toxicity in bone including risk for posttreatment fracture, abnormal healing, and physeal injury in children [7, 15, 19, 24, 25, 51] . Therefore, a better understanding of the complications that may arise in those treated with radiation is important to optimizing care of these patients. Finally, patient functional outcomes using a validated scoring method have not been previously studied in patients with NHL in the appendicular skeleton. With the aim of better understanding the clinical features of NHL of bone, including the efficacy and morbidity risk of contemporary therapies, we examined 70 patients with NHL of bone diagnosed at our tertiary care institution between 1985 and 2013.
The objective of this study was to compare patients treated for NHL of bone with and without radiation in terms of (1) OS; (2) pretreatment complications; (3) posttreatment complications; and (4) functional outcomes using the Musculoskeletal Tumor Society (MSTS) score.
Patients and Methods
After institutional review board approval, we conducted a retrospective study of all patients with NHL of bone diagnosed at our institution between 1985 and 2013. The departments of pathology and hematology/oncology were queried to identify cases of bone lymphoma diagnosed at our institution between 1985 and 2013. Criteria for patient inclusion in our study were biopsy-proven NHL occurring in bone and a minimum clinical followup of 6 months [14, 16] . Criteria for exclusion included (1) unclear diagnosis;
(2) diagnosis of Hodgkin's lymphoma; and (3) diagnosis of T-cell lymphoma.
Medical records were reviewed for patient age, sex, race/ethnicity, biopsy technique, histopathology, lymphoma site, presenting symptoms, imaging, staging, treatment, and orthopaedic complications. Typical staging workups included a bone scan, CT of the chest, abdomen, and pelvis, bone marrow biopsy, and positron emission tomography (PET; 40 patients) or gallium scan. Records were reviewed for chemotherapy regimen, use of rituximab, consolidative radiotherapy, and patient response to treatment. Treatment and followup were instituted by the treating medical oncologists. Routine indications for consolidative radiotherapy included (1) the presence of bulky disease; (2) treatment with an abbreviated course of systemic therapy; and (3) incomplete response to induction therapy (eg, persistent PET activity after completion of systemic therapy). Seventy patients were treated with systemic therapy and 24 of 70 patients (34%) underwent consolidation therapy with external beam radiation (mean dose, 39 Gy; range, 30-54 ± 6). Pretreatment complications, posttreatment complications, and indications for surgery were also reviewed. Fracture outcomes were reviewed for evidence of healing, delayed union, nonunion, and malunion. Variability exists in the definitions of fracture healing [6] ; for the purpose of our study, delayed union was defined as union after 6 months and nonunion was defined as failure of union by 9 months [18, 47] . Union times for pretreatment fractures were estimated from the date the patient completed three cycles of systemic therapy. Union times for posttreatment fractures were estimated from the date of detection. Healing with nonanatomic alignment was considered malunion.
Patients with primary and secondary lymphoma of bone (PLB, SLB) were included in our study. Differentiation can be challenging and was based on guidelines adapted from the World Health Organization ( [49] ; Table 1 ). Bone marrow involvement did not preclude classification as PLB, but indicated advanced disease [1, 43] . Patients with a history of nonosseous lymphoma were considered to have SLB unless histopathology was inconsistent with secondary disease. Patients were categorized into one of two treatment groups: those treated with systemic therapy alone (chemotherapy, rituximab) and those treated with combined modality therapy (CMT; systemic therapy and radiotherapy). Functional evaluation was completed at the conclusion of the study period for all living patients with appendicular tumors using the MSTS scoring system [20] . Scores were available for 45 patients (87% [45 of 52]) at a median followup of 42 months (range, 10-215 months). Comparisons were made on the basis of treatment group, limb involvement (upper extremity [UE] versus lower extremity [LE]), fracture at presentation, and secondary complications. Ten patients with appendicular lesions, including four with posttreatment complications, died and could not be evaluated (16% [10 of 62]).
Treatment groups were compared for differences in demographic features, lymphoma presentation site (weightbearing versus nonweightbearing bones), extent of disease (localized versus advanced), histopathologic subtype (diffuse large B-cell lymphoma [DLBCL] versus indolent lymphoma), primary compared with secondary disease, and systemic therapy (use of rituximab and use of an anthracycline-based chemotherapy regimen; Table 2 ). Localized disease was defined as lymphoma limited to a single bony site with or without involvement of the regional nodes, a definition consistent with Stage 1E and 2E disease per the Ann Arbor staging system [11] . Patients with polyostotic disease, diffuse lymphadenopathy, visceral involvement, or involvement of the bone marrow were considered to have advanced disease (Stages 3E and 4E). Indolent lymphomas included follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, and Waldenström macroglobulinemia.
The records of 99 patients with newly diagnosed lymphoma of bone were screened ( Fig. 1 ). Of 99 patients, five met criteria for exclusion (5%; \ 6 months clinical followup, n = 4; T-cell lymphoma, n = 1) and 22 patients (22%) with deficient records could not be analyzed. In addition, two patients (2%) who were not treated were not included in our analysis. The final study population consisted of 42 men (60%) and 28 women (40%) who met the criteria for inclusion ( Table 2) . None of these patients had been lost to followup. Patient mean age at diagnosis was 54 years (range, 16-81 ± 18 years). Most patients were white and of non-Hispanic ethnicity (n = 49 [70%]). Sixtytwo patients presented with appendicular tumors (89%; LE = 39, UE = 23). Six patients presented with tumors in the spine and two with tumors in the skull. Most tumors occurred in the long bones (n = 42 [60%]; Table 3 ). The majority of patients had pain at the site of disease and 23 (33%) had B symptoms at presentation (fever, chills, night sweats, or weight loss). The most common histopathologic diagnosis was DLBCL (n = 58 [83%]). Forty-two patients (60%) met criteria for PLB. Fifty-one patients had monostotic disease, and 19 were discovered to have polyostotic disease. There was equal representation of patients with localized disease and patients with advanced disease with 35 patients in each category.
Patient OS was defined as the time from patient diagnosis to mortality from any cause. Date of death was confirmed in the Social Security Death Index [45] . Survival curves were formulated using the Kaplan-Meier method [30] . A log-rank test was used to compare survival between patient treatment groups. With the available sample size, it was estimated that a difference in survival of approximately 30% would have to be present for detection with 80% power (a = 0.05, b = 0.2, n = 70, D = 30%). Continuous variables were compared by independent t-test. Categorical variables were compared by chi square and Fisher's exact tests. Statistical analyses were completed in Table 1 . Primary versus secondary NHL of bone*
Group
Description Designation 1 Monostotic disease with or without involvement of the regional nodes PLB 2 Polyostotic disease without involvement of the viscera or diffuse involvement of the lymph nodes PLB 3 Diffuse lymph node involvement or involvement of the viscera is discovered in a patient presenting with a bone tumor 
Results
With the data available, no difference in survival was observed at 5 or 10 years between patients treated with systemic therapy alone and those treated with CMT. Sixteen percent of the study population had died (11 of 70 patients) by the end of the study period with an average time-to-death of 120 months after diagnosis (range, 17-256 ± 67 months). The OS for the entire study population was 97% (95% confidence interval [CI], 92%-100%) at 5 years and 77% (95% CI, 59%-95%) at 10 years ( Fig. 2A ). In 46 patients treated with systemic therapy alone (66% [46 of 70]), OS was 98% (95% CI, 93%-100%) at 5 years and 83% (95% CI, 63%-100%) at 10 years. OS in 24 patients (34% [24 of 70]) who were treated with CMT was 95% (95% CI, 85%-100%) at 5 years and 71% (95% CI, 42%-100%) at 10 years. No difference in survival was observed between treatment groups (p = 0.281; Fig. 2B ). Independent analysis was carried out for 42 patients with PLB (60% [42 of 70]); OS was 97% (95% CI, 91%-100%) at 5 years and 89% (95% CI, 73%-100%) at 10 years and survival did not differ between treatment groups (p = 0.953; Fig. 2C-D) . A proportionate number of patients in each group presented with pathologic fractures; however, problems with fracture healing were more prevalent in those treated with radiation ( Table 4 ). Fracture at presentation was observed in 35% (16 of 46) treated with systemic therapy alone and 21% (five of 24) treated with CMT (p = 0.227). Surgical stabilization was attempted in 38% of those treated without radiation (six of 16) and 20% (one of five) of those treated with CMT. Abnormal fracture healing was observed in 6% (one of 16) unexposed to radiation and 80% (four of five; Fig. 3 ) irradiated at the site of disease (relative risk [RR], 12.8; 95% CI 1.8-89.8; p = 0.01). Treatment with radiation was also associated with risk for secondary fracture and abnormal fracture healing ( Table 5 ). Patients treated with radiation had a greater risk of sustaining fractures in the posttreatment period (five of 24 versus no radiation zero of 46; RR, 20.7; 95% CI, 1.2-359.0; p = 0.0375). Surgical stabilization was attempted in 60% (three of five) after fracture. Most displayed abnormal fracture healing including delayed union, nonunion, and malunion (Figs. 4, 5 ). It cannot be confirmed from the data, however, that these complications occurred as a result of radiation exposure rather than from errors in patient management or the result of patient factors (eg, low bone density).
Functional outcomes data indicated that patients treated with radiation experienced poorer outcomes than those treated without radiation ( Table 6 ). Mean MSTS score in 33 patients (73%) treated with systemic therapy alone was 91% and 75% in 12 (27%) patients treated with CMT (p = 0.034). Seven patients (16% [seven of 45]) experienced secondary complications (six of the patients were in the radiationtreated group) and reported poorer outcomes compared with patients who did not have complications after treatment (p = 0.007). Outcomes did not differ between the treatment groups based on limb involvement or fracture at presentation (p = 0.093, p = 0.887, respectively).
Discussion
Management of patients with NHL of bone has changed over time. Treating patients with surgical resection has fallen out of favor in light of superior survivorship with nonoperative therapies, including radiation, chemotherapy, and the addition of rituximab [43] . The role of [1, 9, 12, 36, 41] . The natural history of NHL of bone is incompletely understood, and patient functional outcomes after treatment have not been well studied. We retrospectively examined patients with NHL of bone diagnosed at our tertiary care institution during a 28-year period. We failed to observe a clear survival advantage in patients treated with radiotherapy and observed a high rate of orthopaedic complications occurring in patients treated with radiation. In addition, we present functional assessment of patients treated for NHL of bone and show inferior functional outcomes in patients treated with radiation.
Our study had several limitations. First, selection bias must be considered when interpreting our results due to the retrospective nature of the study and our inability to randomly assign patients to treatment groups. Treatment selection was strongly influenced by disease stage, patient factors (eg, poor tolerance of chemotherapy), and clinician preference. In general, consolidative radiotherapy is favored in patients with localized disease to prevent local treatment failure but may also be administered to patients with advanced disease if the primary site of disease is bulky [17, 44] . Second, substantial risk remains for type II error (the inability to observe a true difference in survival between the treatment groups), despite the relatively large study population. With the present sample size, a difference in survival of approximately 30% would have had to be present for detection with 80% power. Third, four patients did not meet the minimum followup requirement of 6 months and were excluded from the study. More significantly, 22 patients, the majority of whom were diagnosed early during the study period, could not be analyzed because of incomplete or unavailable records.
We compared survival outcomes between two statistically similar groups of patients completing treatment with systemic therapy alone or CMT. We observed excellent survival outcomes in both groups and failed to observe a significant survival advantage with radiotherapy. Instead, we observed an increased risk for bony complications in patients treated with radiation. Survival outcomes were similar when analysis was restricted to patients with PLB. Similar to earlier studies involving patients with NHL of bone, we observed a male predominance, a predisposition for older adults, and a predilection for involvement of long bones with the disease [1, 29] . We confirmed DLBCL to be the most common histopathologic variant and verified pain as the most common presenting symptom [1, 2, 22, 23] . Early studies concerning bone lymphoma highlighted the integral role of systemic therapy and the insufficiency of monotherapy with radiation or surgery [3, 21, 53] . The efficacy of radiation as an adjunct came under question in lieu of recent studies demonstrating excellent survival outcomes with systemic therapy alone, particularly with the addition of rituximab [1, 12, 13, 41] . Several studies, however, have continued to support the continued use of radiation combined with chemotherapy in adults (CMT) [5, 14, 28, 40] . Management of patients with NHL of bone has become largely nonoperative, but surgical intervention remains critical in the management of disease-related complications as well as complications associated with treatment. We observed a high rate of bony complications occurring at patient presentation with a pathologic fracture rate of 30% and overall orthopaedic complication rate of 36%. Roughly half of the patients required operative care and just more Table 5 . than one-third of patients presenting with fractures were stabilized surgically. Nonoperative management of selected fractures, however, did permit successful healing once oncologic care had been initiated. Conversely, fracture displacement and irradiation of the fracture site were associated with abnormal fracture healing, including delayed union, malunion, and nonunion. Radiation-related alterations in fracture healing, including poor progression between the biomechanical stages of healing and a higher susceptibility to failure in torsion, have been demonstrated in animal models [8, 35, 38] . Prolonged healing times and high rates of nonunion after radiotherapy have also been demonstrated in patients undergoing treatment for soft tissue malignancies [27, 32] . As an additional consequence, the inertness of the irradiated bone creates challenges in achieving operative fixation [10] . As such, advanced surgical techniques, including fracture site resection and grafting, are often necessary to achieve union [10] .
We also observed a high rate of bony complications arising later in the disease course and occurring predominantly in patients treated with radiation. A significant relationship was observed between treatment with radiotherapy and the occurrence of posttreatment fractures, which supports earlier studies demonstrating an increased risk of fracture in patients with NHL of bone, who were treated with radiation, particularly in high doses [33, 46] . Other studies have also shown fractures to occur multiple years after radiation treatment and some investigators have suggested that fracture risk does not decrease over time [4, 26, 31, 37] . Risk of fracture in our study did not appear to be related to the age or sex of the patient. Each fracture occurred in a weightbearing bone, although the distribution of weightbearing lesions was similar between the irradiated and nonirradiated cohorts. Once again, we observed a troublesome pattern of suboptimal bone healing with the majority of patients undergoing surgical intervention. Long-term disability was observed in these patients and in patients with pretreatment fractures who experienced difficulties with healing. Given the debated use of radiotherapy, we have concerns that such complications may represent unnecessary patient morbidity. It may be reasonable to avoid radiation and the associated complications in the treatment of NHL of bone. Alternatively, lower doses of radiation or different strategies for delivery may lessen these complications.
We have provided the first functional assessment of patients treated for NHL occurring in bone and demonstrated outstanding functional outcomes for patients in the absence of bony complications. The majority of patients achieved an ''excellent'' outcome with many reporting a perfect score at final followup. Pain often resolved within weeks of initiating systemic therapy and outcomes did not differ by disease site. Notably, we observed no difference in outcomes of patients presenting with pathologic fractures and patients presenting without fracture. Poorer outcomes, however, were observed in responding patients who had experienced secondary complications, the majority of which occurred in patients treated with radiation. Our results suggest that patients with NHL of bone can be reasonably expected to return to a premorbid level of function after an uncomplicated treatment course. Because there was no observable benefit from receiving radiotherapy with respect to survival with the numbers we had in this study, it might be reasonable to conduct larger, prospective studies assessing whether radiation is necessary in treatment of patients with NHL of bone. Several topics of interest in patients with lymphoma of bone were not examined in this study. Local disease recurrence has been a key subject of interest in these patients, and its prevention has been the primary rationale for consolidative radiotherapy. Interestingly, studies investigating this endpoint, primarily in patients with PLB, have consistently demonstrated the site of relapse to be distant from the original site of disease. In fact, local disease failure appears to be a rare phenomenon irrespective of treatment with radiation [42] . These findings have supported rising skepticisms regarding the essentialness of radiotherapy, particularly in the era of rituximab. Similarly, guidelines for disease surveillance in patients with lymphoma of bone are not well established. Integrated PET-CT has emerged as the imaging modality of choice in patients with fluorodeoxyglucose-avid tumors including most subtypes of lymphoma [52] . Previously, and during the earlier portion of our study period, gallium scintigraphy routinely complemented traditional CT evaluation for staging, response assessment, and surveillance. The optimal frequency of surveillance scans is controversial [48] . Reassessment with plain radiographs and PET may suggest relapse (or complication) in patients with recurrent symptoms; however, repeat biopsy is the only means of definitely proving recurrence.
In conclusion, patient clinical outcomes following treatment for NHL of bone are excellent with contemporary therapies. The survival benefit of radiation use, however, remains debatable. Patient functional outcomes are similarly excellent in the absence of complications that have been associated with radiation. We suggest that further study regarding the necessity of radiation in treatment of lymphoma of bone be conducted in larger, prospective studies. * Secondary complications included those occurring during management of pre-treatment complications and complications arising in the posttreatment period; secondary complications occurred in seven patients (six treated with radiation) and included posttreatment fracture with abnormal healing (3), nonunion of pretreatment fracture (2), malunion of pretreatment fracture (1), and nonhealing defect requiring debridement and graft placement (1); à mean ± SD. MSTS = Musculoskeletal Tumor Society; ST = systemic therapy alone; CMT = combined modality therapy; N/A = not applicable.
